Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jonathan Thon
University of Washington, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Platelet BioGenesis
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Thon is a co-founder of, and has an equity interest in, Platelet BioGenesis, a start-up company that aims to produce donor-independent human platelets from human induced pluripotent stem cells at scale.
The Office for Interactions with Industry (OII,) together with the Committee on Outside Activities (COA) Financial Interest Review Panel (“the Panel”) reviewed Dr. Thon’s financial interest in Platelet BioGenesis in connection with this award. The research aims to engineer universal donor human and mouse pluripotent stem cells that can be differentiated into megakaryocytes that will not be rejected after transplantation and will produce platelets that will not be cleared by circulating antibodies.
Upon review, the Panel determined that Dr. Thon’s financial interest in Platelet BioGenesis creates a financial conflict of interest with this research. The research is demonstrating proof of concept for the generation of universal platelets from human induced pluripotent stem cell-derived megakaryocytes. The research could affect the value of technology that is licensed to Platelet BioGenesis, from BWH, and Platelet BioGenesis would be interested in new IP resulting from this research. The Panel further determined however that Dr. Thon can proceed with the research pursuant to an FCOI management plan that addresses any conflict concerns that arise due to the financial interest.
Universal Donor Megakaryocytes
PUBLIC HEALTH RELEVANCE Project Relevance The proposed research will engineer universal donor human and mouse pluripotent stem cells (PSCs) that can be differentiated into megakaryocytes (MKs) that will not be rejected after transplantation. These MKs will produce platelets that will not be cleared by circulating antibodies, which will be demonstrated in vivo in mouse MK infusion experiments. Our goal is to solve the major clinical problem of life-threatening bleeding in platelet transfusio-refractory patients, and accelerate the use of PSC-derived cells in clinical trials.
Filed on December 11, 2015.
Tell us what you know about Jonathan Thon's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Jonathan Thon”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jonathan Thon | Brigham and Women's Hospital | Conflict of Interest | Platelet BioGenesis | Value cannot be readily determined |
| Jonathan Thon | Brigham and Women's Hospital | Conflict of Interest | Platelet BioGenesis | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.